1. Dear Drugs-Forum readers: We are a small non-profit that runs one of the most read drug information & addiction help websites in the world. We serve over 4 million readers per month, and have costs like all popular websites: servers, hosting, licenses and software. To protect our independence we do not run ads. We take no government funds. We run on donations which average $25. If everyone reading this would donate $5 then this fund raiser would be done in an hour. If Drugs-Forum is useful to you, take one minute to keep it online another year by donating whatever you can today. Donations are currently not sufficient to pay our bills and keep the site up. Your help is most welcome. Thank you.
    PLEASE HELP

Mu-Opioid Receptor PZM21 has Science Hopeful in Fight Against Opioid Addiction

Rating:
5/5,
  1. Beenthere2Hippie
    Once people realized that opioid drugs could cause addiction and deadly overdoses, they tried to use newer forms of opioids to treat the addiction to its parent. Morphine, about 10 times the strength of opium, was used to curb opium cravings in the early 19th century. Codeine, too, was touted as a nonaddictive drug for pain relief, as was heroin.

    Those attempts were doomed to failure because all opioid drugs interact with the brain in the same way. They dock to a specific neural receptor, the mu-opioid receptor, which controls the effects of pleasure, pain relief and need. Now scientists are trying to create opioid painkillers that give relief from pain without triggering the euphoria, dependence and life-threatening respiratory suppression that causes deadly overdoses.

    That wasn't thought possible until 2000, when a scientist named Laura Bohn found out something about a protein called beta-arrestin, which sticks to the opioid receptor when something like morphine activates it. When she gave morphine to mice that couldn't make beta-arrestin, they were still numb to pain, but a lot of the negative side effects of the drug were missing. They didn't build tolerance to the drug. At certain dosages, they had less withdrawal. Their breathing was more regular, and they weren't as constipated as normal mice on morphine.

    Before that experiment, scientists thought the mu-opioid receptor was a simple switch that flicked all the effects of opioids on or off together. Now it seems they could be untied. "The hope is you'd have another molecule that looks like morphine and binds to the same receptor, but the way it turns the receptor on is slightly different," says Dr. Aashish Manglik, a researcher at Stanford University School of Medicine who studies opioid receptors.

    After Bohn's discovery, a number of people, including a team that includes Manglik, started looking for a drug that could connect to the mu-opioid receptor in a way that avoids the negative effects of beta-arrestin. To do that, they mapped the receptor's structure in a computer program and started looking for chemicals that would stick to it. "We tried to look for molecules that would still bind to this 3D structure, but are as far away from morphine and codeine as possible," Manglik says.

    The team ran 3 million possibilities through the computer and picked the 23 best candidates to test in a lab. One chemical, PZM21, seems to do what they hoped: Turn the opioid receptor on without using much beta-arrestin. They report their findings in Nature on Wednesday.

    The scientists then tweaked the chemical to make it more potent and gave it to mice. The mice had pain reduction similar to that with morphine. But their breathing was more normal, and they didn't seem to get high.

    "If you give a mouse a drug that activates its reward pathways like cocaine, amphetamine or morphine, the mice just run around more. In this compound, we saw very little of that," Manglik says. The mice also didn't seem to have a preference between the chemical and salt water. That means it's possible that the compound is less lethal and has less potential for abuse compared to something like morphine, but it still might be as effective of a painkiller. If, of course, it turns out to work in humans. So far it's only been tested in mice.

    And the role that beta-arrestin plays in opioids is just one hypothesis. It would be eerily convenient if only the negative effects of opiates are tied to this one protein. The mice that didn't have any beta-arrestin actually seemed to have a stronger preference for morphine over saline. So there may be other things going on that science hasn't teased out yet. But the work that Manglik and his collaborators have done is encouraging in the search for the next generation of painkillers – ideally ones that are safer and non-addictive.

    "I think this was really a tour de force," says Gavril Pasternak, a researcher at the Memorial Sloan Kettering Cancer Center who's also trying to develop new opioids but was not involved in this study. "They're new entities with totally different pharmacological profiles. These are great promise for opiates over the course of the next 5 to 10 years."

    Bohn, now a professor at The Scripps Research Institute in Jupiter, Fla., is hopeful that a safer opioid may be coming to the clinic, too. Manglik and some of his collaborators have founded a company that will try to bring these new drugs to market, and the pharmaceutical company Trevena is running very similar molecule through clinical trials now. But that safe, effective painkiller isn't here yet, Bohn says.

    "We have some really gorgeous compounds, and I think opiates are a terrible epidemic. But I would be careful of overselling this as the answer."


    By Angus Chen - NPR/Aug. 17, 2016
    http://www.npr.org/sections/health-...an-opioid-that-may-reduce-pain-with-less-risk
    Photo: TS Photography, getty
    Newshawk Crew

    About Author

    Beenthere2Hippie
    BT2H is a retired news editor and writer from the NYC area who, for health reasons, retired to a southern US state early, and where BT2H continues to write and to post drug-related news to DF.

Comments

  1. Beenthere2Hippie
    Hope for the End of the Opiate Crisis

    [IMGL=white]https://drugs-forum.com/forum/attachment.php?attachmentid=51775&stc=1&d=1471467822[/IMGL]It happens every time James Zadina publishes a new paper or receives a write-up: the phone in his New Orleans laboratory begins to ring. The e-mails flood his in-box. The messages come from people all around the nation telling him how much they hurt.

    “I get calls saying, ‘I have this terrible pain. When’s your medicine coming?’” Zadina says. “And my response is, ‘I can’t give it to you now. I’m working as fast as I can.’ That’s all I can say. But it’s difficult.”

    For the last 20 years, Zadina, a researcher at the Tulane School of Medicine and the Southeast Louisiana Veterans Health Care System, has been on the front lines of a battle to defeat an ancient human adversary: physical pain. But lately his work has taken on new urgency. As opioid-related deaths and addiction in the United States reach epidemic proportions, Zadina has been attempting to engineer a new kind of painkiller that wouldn’t have the devastating side effects often caused by commonly prescribed drugs such as Oxycontin.

    His pursuit is difficult because the very mechanisms that make those pills good at dulling pain are the ones that too often lead to crippling addiction and drug abuse. Like their close chemical cousin heroin, prescription opioids can cause people to become physically dependent on them. Researchers have been trying for decades to “separate the addictive properties of opiates from the pain-reducing properties,” says David Thomas, an administrator at the National Institute on Drug Abuse and a founding member of the NIH Pain Consortium. “They kind of go together.”

    But Zadina believes he is getting close to decoupling them. Just this past winter, he and his team published a study in Neuropharmacology reporting that they had treated pain in rats without causing the five most common side effects associated with opioids, including increased tolerance, motor impairment, and respiratory depression, which leads to most opioid-related deaths. The next step is to test it in humans.

    It’s just one of a number of efforts that aim to end the long-term damage that is being caused by relieving people of agony. Up to 8 percent of patients prescribed narcotic painkillers for chronic pain will become addicted, according to the National Institute of Drug Abuse. That’s why it used to be relatively difficult for patients to obtain opioids such as codeine to treat pain, Thomas says. That began to change in the 1990s. New opioids such as Oxycontin (and new marketing campaigns by pharmaceutical companies) arrived to meet the earnest demands of pain doctors and patient advocates who argued that many people with chronic pain—which afflicts an estimated 100 million Americans—were needlessly suffering.

    But the pendulum has swung so far that opioids have become the default drug even when there might be better alternatives. Dan Clauw, director of the Chronic Pain and Fatigue Research Center at the University of Michigan, says that too many doctors now are essentially telling patients, “Well, I was taught that opioids would always work in any kind of pain, and if the pain’s bad enough and you’re desperate enough, I’ll try this class of drugs even if I am concerned about the risk of addiction.”

    The consequences have been devastating. In 2014, the number of deaths from opioid overdoses in the United States topped 18,000, about 50 a day—more than three times the number in 2001. And that doesn’t even take into account painkiller addicts who have turned to heroin to soothe their cravings. Officials at the Centers for Disease Control and Prevention recently compared the scale of the problem to the HIV epidemic of the 1980s.

    Developing any kind of better painkiller is very hard largely because pain takes complex pathways in our bodies. The signals that reach the brain and are interpreted as pain sometimes come from a problem on the periphery, or the surface, of our bodies, like when you get a cut. Other times the source of the pain signals is deeper: from damage to our nerves, which can happen with a really bad wound or, say, a back injury. And researchers such as Clauw are now finding evidence that much pain comes from a third type of situation: misfiring in the brain.

    However, the presence of these different pain mechanisms also means there are a few different ways to try to solve the opioid problem. While Zadina and other scientists try to remove the dangerous properties from opioids, other new painkillers might target altogether different mechanisms in the body.

    Make it stop

    The main way to kill pain is simply to reduce the signals that the body feeds to the brain.

    Nearly all our tissues have what are known as “nociceptive” nerve endings, tiny fibers whose job is to collect information and convey it back to the central nervous system and into the brain for processing. These fibers act as pain sensors. Some of the nerve endings respond to pressure, which causes them to send electrical impulses to the spinal cord so we actually feel hurt. Other kinds of nerve endings respond to changes in temperature, generating pain signals when things get too hot or cold. When we sustain an injury, inflammatory cells are recruited to the site and release at least a dozen different chemicals aimed at triggering other cells to come in and fight off pathogens, clean up debris, and begin rebuilding. But these inflammatory cells also cause the nerve endings at the site of the injury to fire more pain signals. In this type of localized injury, such as a sprained ankle or twisted knee, ice or anti--inflammatory drugs such as ibuprofen can be enough to tamp down the pain signals.

    But sometimes—after a severe injury, an amputation, or diabetic nerve damage, for example—nerve fibers or the cells from which they originate physically change. Deep inside them, some genes can get turned on or off. That changes the number or type of active cellular machines known as sodium channels—proteins that stick out of the cells and regulate their ability to generate electrical impulses. Nerve cells talk to each other by means of these electrical impulses, and the sudden activity of extra sodium channels can cause a nerve to fire machine-gun-like bursts “spontaneously, even when there are no threatening stimuli,” explains Stephen Waxman, a professor of neurology at Yale University who directs the Center for Neuroscience and Regeneration Research at a Veterans Affairs hospital in Connecticut. Those bursts leave people in extreme pain. One common cause is chemotherapy. “Sometimes that pain is so bad people say ‘I can’t stand it,’” Waxman says. “‘I would rather die from cancer than have the pain associated with treatment.’”

    There are nine kinds of sodium channels; the numbing medicine you get in the dentist’s office works by locally blunting all of them. That wouldn’t work as a general pain medication, because some of these channels are present in the brain and central nervous system. But Waxman is part of a cadre of researchers hunting for ways to target just one key sodium channel. He discovered its importance by studying people who have a rare genetic mutation that prevents them from making this particular channel. Even though the channel is not found everywhere in the human body, they essentially go through life feeling no pain. Conversely, people born with a hyperactive version of it feel as though “lava has been poured into their bodies,” Waxman says.

    A drug developed by Pfizer, based on Waxman’s discoveries, has been tested on five patients, and similar painkillers are in development. Theoretically at least, these would not have major side effects.

    Which brings us back to opioids.

    Flipping a switch

    Our peripheral nerves, where we pick up pain signals, lead back to the spinal column, where they connect with nerve cells that carry messages into the central nervous system and to neurons in the brain, at which point we feel the pain.

    This is where all opioids, from Oxycontin to heroin and morphine, work their magic. They do so by binding to what are known as mu receptors at the junctions where nerve cells meet. That essentially flips a switch that reduces the ability of these cells to fire. So when nerve fibers at the periphery of the body send pain signals up to the brain for processing, the neurons that would normally make us feel this pain don’t respond.

    “Opioids don’t touch the pain source; they only turn off the appreciation of the pain in the brain,” says Lewis Nelson, a professor of emergency medicine at New York University School of Medicine, who sat on a panel that recently recommended opioid guidelines for the Centers for Disease Control. “A small dose of an opioid just changes the sensation from being something that is quite irritating to being something that you don’t seem to care about as much.”

    Mu receptors respond not only to painkilling drugs but also to “endogenous opioids,” natural signaling agents produced by our bodies—like the endorphins that are released during exercise, producing the so-called “runner’s high.” The problem is that the body doesn’t seem to respond to drugs such as heroin and Oxycontin in the same way it does to the endogenous substances.

    Unlike endogenous opioids, pain drugs often activate specialized cells in the central nervous system, known as glia. Glia clean up cellular debris in the body and help regulate the response to injuries to the central nervous system. But when activated, they produce inflammatory substances—which can cause the body to register more pain signals. Many researchers, in fact, believe this increased activation of glial cells may be what causes the dangerous buildup of tolerance that makes opioids less effective over time, so that a patient needs higher doses to feel their effects. Eventually those higher doses can cause deadly respiratory problems.

    All this might be avoided if Zadina can finally develop a synthetic opioid more like the body’s own substances—one that hits the mu receptors without activating glial cells. In the 1990s, he and his team isolated a previously undiscovered neurochemical in the brain, a pain-numbing substance they named endomorphin. He has been attempting ever since to perfect synthetic versions of it.

    One of those versions was the drug that Zadina tested on rats in the study reported this past winter in Neuropharmacology. Like some of his previous compounds, this version appeared to be as good as or possibly better than morphine at relieving the animals’ pain without causing the worst side effects. Now he is in talks with several investors and biotech companies interested in turning it into a pill for people. Once he and his collaborators raise the money to start their own company, or ink a deal with a licensing partner, they intend to seek approval for early-stage human trials. “You never know until you actually put it in humans,” he says.

    Zadina’s drug would still be likely to activate the reward areas of the brain, and it might generate a mild high that could predispose some to addiction. But the rapid escalation of tolerance that opioids normally cause—and the physical withdrawal symptoms people endure when they stop taking them—would probably be removed from the equation. “I want to take away the dilemma that both patients and physicians face, of ‘Do I treat this pain adequately and risk addiction or do I treat the pain inadequately because I don’t want to use opioids?’” Zadina says. “That’s what drives me.”

    But even if his new drug succeeds, neither it nor new sodium-channel painkillers are likely to treat a type of pain we weren’t even sure existed until recently—pain that does not seem to respond at all to opioids. Michigan’s Clauw has been studying this kind of pain for the past 20 years. From brain imaging studies, he has determined that it is caused by misfiring in the brain rather than a problem at the site where the pain seems to be coming from. He contends that this is the most common reason for pain in younger people suffering from conditions that have long confounded doctors, including fibromyalgia, certain headaches, and irritable bowel syndrome. What should those patients take instead of the opioids they are often prescribed? Many of them, Clauw argues, should be on drugs that can actually halt the misfiring by boosting neurotransmitters. Some drugs originally developed as antidepressants achieve this.

    The NIH’s Thomas points to Clauw’s research as evidence that opioids today are simply overprescribed.

    “If you get in a car accident, get wounded in battle, your arm gets blown up or something, and you’re in really severe pain, they will knock out severe pain pretty darn quickly,” says Thomas. “But right now they’re being used for all sorts of other cases where they’re probably not beneficial to the patient in the long run.”

    Adam Piore is the author of  The Body Builders: Inside the Science of the Engineered Human, which will be published in February.


    By Adam Piore - MIT/Aug. 11, 2016
    https://www.technologyreview.com/s/602141/the-painkillers-that-could-end-the-opioid-crisis/
    Photo: Kimberly White, getty
    Newshawk Crew
To make a comment simply sign up and become a member!